Date: 2012-05-14
Type of information: Collaboration agreement
Compound: novel class of compounds to maintain neuromuscular junction strength and stability
Company: Neurotune (Switzerland) The ALS Therapy Development Institute - ALS TDI (UK)
Therapeutic area: Neurodegenerative diseases - Rare diseases
Type agreement:
Action mechanism:
Disease: amyotrophic lateral sclerosis
Details: The ALS Therapy Development Institute (ALS TDI) has entered into collaboration with Neurotune to investigate a potential treatment for amyotrophic lateral sclerosis (Lou Gehrig’s disease). In ALS, motor neurons and their axons become disconnected from the muscle. Maintaining connectivity at this “neuromuscular junction” is crucial to a person’s ability to freely move, eat and breathe independently, all functions that are gradually lost as ALS progresses. Neurotune has developed a novel class of compounds to maintain neuromuscular junction strength and stability. Under the terms of the agreement, ALS TDI will use one of those compounds in a preclinical model of ALS to determine if the treatment has an effect on disease course.
Financial terms:
Latest news:
